TREATMENT OF LATE LYME BORRELIOSIS-RANDOMISED COMPARISON OF CEFTRIAXONE AND PENICILLIN

Raymond J. Dattwyler, David J. Volkman, John Halperin, Benjamin J. Luft

Research output: Contribution to journalArticle

270 Citations (Scopus)

Abstract

23 patients with clinically active late Lyme disease were randomly assigned to intravenous treatment with either penicillin or ceftriaxone. Of the 10 treated with penicillin, 5 were judged treatment failures; of the 13 who received ceftriaxone, only 1 did not respond. An additional 31 patients were subsequently treated with ceftriaxone 4 g/day (n = 17) or 2 g/day (n = 14); successs rates in both groups were comparable to those in the cohort randomised to ceftriaxone. Patients unresponsive to ceftriaxone were more likely to have received corticosteroid treatment.

Original languageEnglish (US)
Pages (from-to)1191-1194
Number of pages4
JournalThe Lancet
Volume331
Issue number8596
DOIs
StatePublished - May 28 1988
Externally publishedYes

Fingerprint

Lyme Disease
Ceftriaxone
Penicillins
Therapeutics
Treatment Failure
Adrenal Cortex Hormones

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Dattwyler, Raymond J. ; Volkman, David J. ; Halperin, John ; Luft, Benjamin J. / TREATMENT OF LATE LYME BORRELIOSIS-RANDOMISED COMPARISON OF CEFTRIAXONE AND PENICILLIN. In: The Lancet. 1988 ; Vol. 331, No. 8596. pp. 1191-1194.
@article{f3d6c76038f643bf85ee6b7f911c5ab5,
title = "TREATMENT OF LATE LYME BORRELIOSIS-RANDOMISED COMPARISON OF CEFTRIAXONE AND PENICILLIN",
abstract = "23 patients with clinically active late Lyme disease were randomly assigned to intravenous treatment with either penicillin or ceftriaxone. Of the 10 treated with penicillin, 5 were judged treatment failures; of the 13 who received ceftriaxone, only 1 did not respond. An additional 31 patients were subsequently treated with ceftriaxone 4 g/day (n = 17) or 2 g/day (n = 14); successs rates in both groups were comparable to those in the cohort randomised to ceftriaxone. Patients unresponsive to ceftriaxone were more likely to have received corticosteroid treatment.",
author = "Dattwyler, {Raymond J.} and Volkman, {David J.} and John Halperin and Luft, {Benjamin J.}",
year = "1988",
month = "5",
day = "28",
doi = "10.1016/S0140-6736(88)92011-9",
language = "English (US)",
volume = "331",
pages = "1191--1194",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8596",

}

TREATMENT OF LATE LYME BORRELIOSIS-RANDOMISED COMPARISON OF CEFTRIAXONE AND PENICILLIN. / Dattwyler, Raymond J.; Volkman, David J.; Halperin, John; Luft, Benjamin J.

In: The Lancet, Vol. 331, No. 8596, 28.05.1988, p. 1191-1194.

Research output: Contribution to journalArticle

TY - JOUR

T1 - TREATMENT OF LATE LYME BORRELIOSIS-RANDOMISED COMPARISON OF CEFTRIAXONE AND PENICILLIN

AU - Dattwyler, Raymond J.

AU - Volkman, David J.

AU - Halperin, John

AU - Luft, Benjamin J.

PY - 1988/5/28

Y1 - 1988/5/28

N2 - 23 patients with clinically active late Lyme disease were randomly assigned to intravenous treatment with either penicillin or ceftriaxone. Of the 10 treated with penicillin, 5 were judged treatment failures; of the 13 who received ceftriaxone, only 1 did not respond. An additional 31 patients were subsequently treated with ceftriaxone 4 g/day (n = 17) or 2 g/day (n = 14); successs rates in both groups were comparable to those in the cohort randomised to ceftriaxone. Patients unresponsive to ceftriaxone were more likely to have received corticosteroid treatment.

AB - 23 patients with clinically active late Lyme disease were randomly assigned to intravenous treatment with either penicillin or ceftriaxone. Of the 10 treated with penicillin, 5 were judged treatment failures; of the 13 who received ceftriaxone, only 1 did not respond. An additional 31 patients were subsequently treated with ceftriaxone 4 g/day (n = 17) or 2 g/day (n = 14); successs rates in both groups were comparable to those in the cohort randomised to ceftriaxone. Patients unresponsive to ceftriaxone were more likely to have received corticosteroid treatment.

UR - http://www.scopus.com/inward/record.url?scp=0023894012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023894012&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(88)92011-9

DO - 10.1016/S0140-6736(88)92011-9

M3 - Article

VL - 331

SP - 1191

EP - 1194

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8596

ER -